Comparative Benchmarking
In the context of the broader market, GALT competes directly with industry leaders such as CRBU and NTHI. With a market capitalization of $172.79M, it holds a significant position in the sector. When comparing efficiency, GALT's gross margin of N/A stands against CRBU's 100.00% and NTHI's 100.00%. Such benchmarking helps identify whether Galectin Therapeutics Inc is trading at a premium or discount relative to its financial performance.
